What Determines Length of Stay for Polysubstance Rehab in California?

When a facility mentions 30, 60, or 90 days, ask whether that number is a common planning window, a minimum commitment, an average, a maximum, or simply an example. Do not assume it is the recommendation for you. Also ask when the recommendation is first made, who participates, what information is considered, and how often it is reviewed.

NIDA's treatment principles emphasize that needs differ and that a plan should address the whole person, not only substance use. For a polysubstance situation, qualified professionals may need accurate information about each substance, recent use, prior treatment, physical and mental health concerns, medications, living conditions, support, and practical obligations. Share what you know without guessing. A missing or uncertain detail can be recorded as unknown rather than filled in from memory under pressure.

• What does the stated number of days mean in this program?
• Is that duration descriptive, contractual, clinically recommended, or coverage-related?
• Who makes an individualized recommendation, and when? recommended for this person? How often is that recommendation reviewed? What happens if needs change? What information shoulds

SAMHSA advises discussing treatment choices with qualified professionals and offers national treatment locators. Its quality guidance supports asking about licensing, accreditation, evidence-supported care, medications when clinically appropriate, family involvement, and continuing-care planning. Ask each facility to explain these points in concrete terms rather than accepting labels alone. Whether a medication is clinically appropriate is a question for qualified professionals, not a conclusion to make from an article.

Build a comparison table in your notes. Use one facility per column and one question per row. Helpful rows include current license details, services verified in public records, assessment process, how plans are individualized, review frequency, medication policies, family involvement options, continuing-care planning, total expected costs, and unresolved questions. Add a confidence label to each cell: confirmed in writing, reported by phone, or unanswered. A blank cell is more honest than an inferred answer.

• Can you identify the applicable license and explain what it covers?
• How does the program define evidence-supported care?
• How are medications considered when clinically appropriate? How can family or chosen supports be involved with consent? When does continuing-care planning begin, and who helps make

Ask for the sequence, not a guarantee. What information is gathered before arrival? What happens during intake? When is an initial plan discussed? When is it reviewed? Who explains changes? What conditions could prompt a different recommendation or a referral elsewhere? A clear process matters more than a confidently quoted number.

Use a checkpoint sheet with spaces for before admission, arrival, initial review, ongoing reviews, discharge planning, and the first continuing-care contact. For each point, write the responsible role, the decision expected, the information needed, and the person you should contact with questions. Do not assume that a tentative admission conversation establishes final acceptance, a room, a schedule, or an outcome.

• What documents and accurate substance-use information should I prepare?
• Which decisions can be made before arrival, and which require an in-person assessment?
• When will the first individualized recommendation be discussed? How will changes be communicated to me or an authorized support person? What planning occurs if this facility is not